Álvaro H Borges1, Jemma L O'Connor2, Andrew N Phillips2, Frederikke F Rönsholt3, Sarah Pett4, Michael J Vjecha5, Martyn A French6, Jens D Lundgren1. 1. Centre for Health and Infectious Diseases Research (CHIP), Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark. 2. Research Department of Infection and Population Health, University College London, United Kingdom. 3. Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark. 4. Research Department of Infection and Population Health, University College London, United Kingdom MRC Clinical Trials Unit, University College London, United Kingdom Kirby Institute, University of New South Wales Australia, Sydney. 5. Institute for Clinical Research, Inc., Veterans Affairs Medical Center, Washington, District of Columbia. 6. School of Pathology and Laboratory Medicine, University of Western Australia Department of Clinical Immunology, Royal Perth Hospital and PathWest Laboratory Medicine, Australia.
Abstract
BACKGROUND: Elevated interleukin 6 (IL-6) levels have been linked to cardiovascular disease, cancer and death. Persons with human immunodeficiency virus (HIV) infection receiving treatment have higher IL-6 levels, but few data are available on factors associated with circulating IL-6. METHODS: Participants in 3 trials with IL-6 measured at baseline were included (N = 9864). Factors associated with IL-6 were identified by linear regression. Demographic and HIV variables (nadir/entry CD4(+) cell count, HIV RNA level, antiretroviral therapy regimen) were investigated in all 3 trials. In the SMART (Strategies for Management of Anti-Retroviral Therapy) trial, CD4/CD8 ratio, smoking, comorbid conditions, serum lipids, renal function (estimated glomerular filtration rate [eGFR]), and educational level were assessed. RESULTS: Demographics associated with higher IL-6 levels were older age and lower education, whereas black race was associated with lower IL-6. Higher HIV RNA levels were associated with higher IL-6 levels, and higher nadir CD4(+) cell counts with lower IL-6 levels. Compared with efavirenz, protease inhibitors were associated with higher and nevirapine with lower IL-6 levels. Smoking and all comorbid conditions were related to higher IL-6. IL-6 levels increased with decreasing eGFR and decreasing serum lipids. CONCLUSIONS: Higher levels of IL-6 were associated with older age, nonblack race, higher body mass index, lower serum lipid levels, HIV replication, low nadir CD4(+) cell count, protease inhibitor use, comorbid conditions, and decreased eGFR. Multiple factors affect inflammation in HIV and should be considered in studies of IL-6 as a biomarker of clinical outcomes.
BACKGROUND: Elevated interleukin 6 (IL-6) levels have been linked to cardiovascular disease, cancer and death. Persons with human immunodeficiency virus (HIV) infection receiving treatment have higher IL-6 levels, but few data are available on factors associated with circulating IL-6. METHODS:Participants in 3 trials with IL-6 measured at baseline were included (N = 9864). Factors associated with IL-6 were identified by linear regression. Demographic and HIV variables (nadir/entry CD4(+) cell count, HIV RNA level, antiretroviral therapy regimen) were investigated in all 3 trials. In the SMART (Strategies for Management of Anti-Retroviral Therapy) trial, CD4/CD8 ratio, smoking, comorbid conditions, serum lipids, renal function (estimated glomerular filtration rate [eGFR]), and educational level were assessed. RESULTS: Demographics associated with higher IL-6 levels were older age and lower education, whereas black race was associated with lower IL-6. Higher HIV RNA levels were associated with higher IL-6 levels, and higher nadir CD4(+) cell counts with lower IL-6 levels. Compared with efavirenz, protease inhibitors were associated with higher and nevirapine with lower IL-6 levels. Smoking and all comorbid conditions were related to higher IL-6. IL-6 levels increased with decreasing eGFR and decreasing serum lipids. CONCLUSIONS: Higher levels of IL-6 were associated with older age, nonblack race, higher body mass index, lower serum lipid levels, HIV replication, low nadir CD4(+) cell count, protease inhibitor use, comorbid conditions, and decreased eGFR. Multiple factors affect inflammation in HIV and should be considered in studies of IL-6 as a biomarker of clinical outcomes.
Authors: Heloísa Ramos Lacerda; Maria da Conceição Correia Falcão; Valéria Maria Gonçalves de Albuquerque; Josefina Claudia Zírpoli; Demócrito de Barros Miranda-Filho; Maria de Fátima Pessoa Militão de Albuquerque; Ulisses Montarroyos; Ricardo Arraes de Alencar Ximenes Journal: J Interferon Cytokine Res Date: 2013-12-20 Impact factor: 2.607
Authors: Daniel Fuster; Judith I Tsui; Debbie M Cheng; Emily K Quinn; Kaku A Armah; David Nunes; Matthew S Freiberg; Jeffrey H Samet Journal: AIDS Res Hum Retroviruses Date: 2013-05-17 Impact factor: 2.205
Authors: John R Koethe; Kevin Dee; Aihua Bian; Ayumi Shintani; Megan Turner; Sally Bebawy; Timothy R Sterling; Todd Hulgan Journal: AIDS Res Hum Retroviruses Date: 2013-04-11 Impact factor: 2.205
Authors: Lars Peters; Jacqueline Neuhaus; Daniel Duprez; James D Neaton; Russel Tracy; Marina B Klein; Amanda Mocroft; Jürgen Rockstroh; Gregory Dore; Jens D Lundgren Journal: J Clin Virol Date: 2014-04-08 Impact factor: 3.168
Authors: Alvaro H Borges; Jemma L O'Connor; Andrew N Phillips; Jason V Baker; Michael J Vjecha; Marcelo H Losso; Hartwig Klinker; Gustavo Lopardo; Ian Williams; Jens D Lundgren Journal: PLoS One Date: 2014-03-13 Impact factor: 3.240
Authors: Sergio Serrano-Villar; Talia Sainz; Sulggi A Lee; Peter W Hunt; Elizabeth Sinclair; Barbara L Shacklett; April L Ferre; Timothy L Hayes; Ma Somsouk; Priscilla Y Hsue; Mark L Van Natta; Curtis L Meinert; Michael M Lederman; Hiroyu Hatano; Vivek Jain; Yong Huang; Frederick M Hecht; Jeffrey N Martin; Joseph M McCune; Santiago Moreno; Steven G Deeks Journal: PLoS Pathog Date: 2014-05-15 Impact factor: 6.823
Authors: Anna D Nordell; Matthew McKenna; Álvaro H Borges; Daniel Duprez; Jacqueline Neuhaus; James D Neaton Journal: J Am Heart Assoc Date: 2014-05-28 Impact factor: 5.501
Authors: Stanzi M le Roux; Jennifer Jao; Kirsty Brittain; Tamsin K Phillips; Seun Olatunbosun; Agnes Ronan; Allison Zerbe; Elaine J Abrams; Landon Myer Journal: AIDS Date: 2017-01-02 Impact factor: 4.177
Authors: Barbara S Taylor; Kaku So-Armah; Janet P Tate; Vincent C Marconi; John R Koethe; Roger J Bedimo; Adeel A Butt; Cynthia L Gibert; Matthew B Goetz; Maria C Rodriguez-Barradas; Julie A Womack; Mariana Gerschenson; Vincent Lo Re; David Rimland; Michael T Yin; David Leaf; Russell P Tracy; Amy C Justice; Matthew S Freiberg Journal: J Acquir Immune Defic Syndr Date: 2017-08-15 Impact factor: 3.731
Authors: Ivan Delgado-Enciso; Brenda Paz-Michel; Valery Melnikov; Jose Guzman-Esquivel; Francisco Espinoza-Gomez; Alejandro D Soriano-Hernandez; Iram P Rodriguez-Sanchez; Margarita L Martinez-Fierro; Gabriel Ceja-Espiritu; Bertha A Olmedo-Buenrostro; Hector R Galvan-Salazar; Osiris G Delgado-Enciso; Josuel Delgado-Enciso; Uriel A Lopez-Lemus; Daniel A Montes-Galindo Journal: Exp Ther Med Date: 2017-12-21 Impact factor: 2.447
Authors: Álvaro H Borges; Jemma L O'Connor; Andrew N Phillips; James D Neaton; Birgit Grund; Jacqueline Neuhaus; Michael J Vjecha; Alexandra Calmy; Kersten K Koelsch; Jens D Lundgren Journal: J Infect Dis Date: 2016-04-30 Impact factor: 5.226
Authors: Brian B Hart; Anna D Nordell; Jason F Okulicz; Adrian Palfreeman; Andrzej Horban; Eynat Kedem; Jacqueline Neuhaus; David R Jacobs; Daniel A Duprez; James D Neaton Journal: J Acquir Immune Defic Syndr Date: 2018-01-01 Impact factor: 3.731